Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma

Background Approximately two-thirds of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) do not respond to or relapse after anti-CD19 chimeric antigen receptor T (CAR T)-cell therapy, leading to poor outcomes. Previous studies have suggested that intensified lymphodepletion and h...

Full description

Bibliographic Details
Main Authors: Wei Liu, Yan Xu, Yi Wang, Huijun Wang, Jun Wei, Lugui Qiu, Huimin Liu, Jianxiang Wang, Weiwei Sui, Yin Shi, Hesong Zou, Wenyang Huang, Shuhua Yi, Dehui Zou, Lianting Chen, Rui Lv, Kefei Wang, Wenjie Xiong, Shuhui Deng, Guangxin Peng, Yueshen Ma, Lulu Lv, Wenting Zheng
Format: Article
Language:English
Published: BMJ Publishing Group 2024-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/4/e008857.full

Internet

https://jitc.bmj.com/content/12/4/e008857.full

Similar Items